Technical Data
I0100-15
I-309, Recombinant, Human
2ug
10ug
Molecular Biology Storage: -20CShipping: RT
The human cytokine I-309 is a small glycoprotein secreted by activated T lymphocytes and structurally related to a number of inflammatory cytokines. Recombinant Human I-309 is a single,non-glycosylated, polypeptide chain containing 74 amino acids and having a molecular mass of 8.504kD.

Sequence:
The sequence of the first five N-terminal amino acids was determined and was found to be Ser-Lys-Ser-Met-Gln.

Dimers and Aggregates:
1% as determined by silver-stained SDS-PAGE gel analysis.

Biological Activity:
Human I-309 is fully biologically active when compared to standard. The Biological activity is calculated by its ability to chemoattract human T cells at 10.0-100.0ng/ml.

Endotoxin:
0.1ng/ug (IEU/ug) of Human HCC-1.

Protein Content:
Protein quantitation was carried out by two independent methods:
1. UV spectroscopy at 280nm.
2. Analysis by RP-HPLC, using a calibrated solution of Human I-309 as a Reference Standard.

Reconstitution:
Reconstitute the lyophilized Human I-309 in sterile 18MO-cm H2O not less than 100ug/ml, which can then be further diluted to other aqueous solutions.

Storage and Stability:
Lyophilized powder may be stored at 4C for short-term only. Reconstitute to nominal volume by adding sterile dH2O and store at -20C. Reconstituted product is stable for 12 months at -20C. For maximum recovery of product, centrifuge the original vial prior to removing the cap. Further dilutions can be made in assay buffer.
Source: E. coli
Purity: 98% by RP-HPLC, FPLC, or reducing/non-reducing SDS-PAGE Silver Stain. Chromatographically purified.
Concentration: ~0.1mg/ml
Form: Supplied as a lyophilized powder. No additives.

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
1. Human cord blood-derived mast cells synthesize and release I-309 in response to IgE. Gilchrest H, Cheewatrakoolpong B, Egan RW, Life Sci 2003 Oct 3;73(20):2571-81 2. CCR8-dependent activation of the RAS/MAPK pathway mediates anti-apoptotic activity of I-309/ CCL1 and vMIP-I. Louahed J, Struyf S, Parmentier M, Eur J Immunol 2003 Feb;33(2):494-501 3. Autocrine antiapoptotic stimulation of cultured adult T-cell leukemia cells by overexpression of the chemokine I-309. Ruckes T, Saul D, Hermine O, Blood 2001 Aug 15;98(4):1150-9 4. Human NK cells express CC chemokine receptors 4 and 8 and respond to thymus and activation-regulated chemokine, macrophage-derived chemokine, and I-309. Inngjerdingen M, Damaj B, J Immunol 2000 Apr 15;164(8):4048-54 5. The chemokine receptor CCR8 mediates human endothelial cell chemotaxis induced by I-309 and Kaposi sarcoma herpesvirus-encoded vMIP-I and by lipoprotein(a)-stimulated endothelial cell conditioned medium. Haque NS, Fallon JT, Harpel PC, Blood 2001 Jan 1;97(1):39-45 6. I-309 binds to and activates endothelial cell functions and acts as an angiogenic molecule in vivo. Bernardini G, Spinetti G, Camarda G, Capogrossi MC, Blood 2000 Dec 15;96(13):4039-45.

Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.